MX2018001568A - Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. - Google Patents

Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.

Info

Publication number
MX2018001568A
MX2018001568A MX2018001568A MX2018001568A MX2018001568A MX 2018001568 A MX2018001568 A MX 2018001568A MX 2018001568 A MX2018001568 A MX 2018001568A MX 2018001568 A MX2018001568 A MX 2018001568A MX 2018001568 A MX2018001568 A MX 2018001568A
Authority
MX
Mexico
Prior art keywords
cells
solid tumor
tumor targeting
bispecific car
chimeric antigen
Prior art date
Application number
MX2018001568A
Other languages
English (en)
Inventor
C Jensen Michael
Original Assignee
Seattle Children´S Hospital Dba Seattle Children´S Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Children´S Hospital Dba Seattle Children´S Res Institute filed Critical Seattle Children´S Hospital Dba Seattle Children´S Res Institute
Publication of MX2018001568A publication Critical patent/MX2018001568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen en la presente métodos para el manejo de una célula T bi-específica que expresa receptores quiméricos de antígeno para promover la expansión y activación in vivo de una célula efectora y un segundo receptor quimérico de antígeno o TcR específico para un ligando en un tumor. También se proporcionan métodos para administrar a sujetos en necesidad, células bi-específicas de receptor quimérico de antígeno.
MX2018001568A 2015-08-07 2016-08-03 Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. MX2018001568A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202698P 2015-08-07 2015-08-07
PCT/US2016/045360 WO2017027291A1 (en) 2015-08-07 2016-08-03 Bispecific car t-cells for solid tumor targeting

Publications (1)

Publication Number Publication Date
MX2018001568A true MX2018001568A (es) 2019-04-25

Family

ID=57984403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001568A MX2018001568A (es) 2015-08-07 2016-08-03 Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.

Country Status (9)

Country Link
US (3) US11458167B2 (es)
EP (1) EP3331920A4 (es)
JP (2) JP7162530B2 (es)
CN (1) CN108174604B (es)
AU (2) AU2016306209B2 (es)
CA (1) CA2994829A1 (es)
HK (1) HK1256087A1 (es)
MX (1) MX2018001568A (es)
WO (1) WO2017027291A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
EP3331920A4 (en) * 2015-08-07 2019-04-03 Seattle Children's Hospital, dba Seattle Children's Research Institute T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING
IL287889B2 (en) * 2016-02-05 2024-03-01 Hope City Administration of transgenic T cells for the treatment of central nervous system cancer
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
EP3551197B1 (en) 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN111315872A (zh) * 2017-06-30 2020-06-19 纪念斯隆-凯特林癌症中心 用于癌症的过继性细胞疗法的组合物和方法
WO2019006468A1 (en) * 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY
CA3068636A1 (en) * 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
AU2018309735A1 (en) * 2017-07-31 2020-02-20 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CN109423495A (zh) * 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 一种双靶向嵌合抗原受体及其用途
AU2018352984B2 (en) 2017-10-18 2024-02-01 Precigen, Inc. Polypeptide compositions comprising spacers
SG11202003866QA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
BR112020008340A2 (pt) * 2017-11-01 2020-11-17 Juno Therapeutics Inc processo para gerar composições terapêuticas de células modificadas
CN111683962A (zh) * 2017-11-10 2020-09-18 美国政府(由卫生和人类服务部的部长所代表) 靶向肿瘤抗原的嵌合抗原受体
DK3720883T3 (da) 2017-12-05 2023-07-24 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct T-celler omfattende kimære anti-cd38- og anti-cd138-antigenreceptorer og anvendelser deraf
US20210300986A1 (en) * 2017-12-05 2021-09-30 The Medical Research Infrastrutrure And Health Services Fund Of The Tel Aviv Medecal Center T-cells comprising two different chimeric antigen receptors and uses thereof
CN109970866B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd28双向激活共刺激分子受体及其用途
CN109970867B (zh) * 2017-12-28 2022-10-18 上海细胞治疗研究院 一种cd40双向激活共刺激分子受体及其用途
CN109970864A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 一种双向激活共刺激分子受体及其用途
US20220265708A1 (en) * 2018-01-11 2022-08-25 Innovative Cellular Therapeutics, Inc. Modified Cell Expansion and Uses Thereof
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
GB201807862D0 (en) * 2018-05-15 2018-06-27 Ucl Business Plc Chimeric antigen receptor
US20210252058A1 (en) * 2018-05-17 2021-08-19 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with myd88 and cd40 costimulatory domains
KR20210018323A (ko) 2018-06-06 2021-02-17 매사추세츠 인스티튜트 오브 테크놀로지 진핵 세포에서의 번역을 위한 원형 rna
CN112334572A (zh) * 2018-06-19 2021-02-05 南特细胞公司 Hiv治疗组合物和方法
WO2020011247A1 (en) * 2018-07-13 2020-01-16 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
CA3107675A1 (en) * 2018-07-30 2020-02-06 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
AU2019317565A1 (en) * 2018-08-08 2021-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
CN110845621A (zh) * 2018-08-21 2020-02-28 上海恒润达生生物科技有限公司 一种靶向egfr和cd19双靶点的嵌合抗原受体方法
JP7386848B2 (ja) * 2018-08-28 2023-11-27 法▲羅▼斯疫苗株式会社 改良されたレンチウイルスベクター
US20220348682A1 (en) 2018-08-30 2022-11-03 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
CN109400710A (zh) * 2018-11-02 2019-03-01 山西大医院（山西医学科学院） 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用
JP2022513099A (ja) * 2018-11-19 2022-02-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 自殺遺伝子
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020123936A1 (en) * 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
CN111748017A (zh) * 2019-03-26 2020-10-09 上海瑞可新生物科技有限公司 一种抗原多肽及其表达载体、组合药物、试剂盒和应用
EP3952885A4 (en) * 2019-04-12 2023-01-18 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS COMPRISING A HIGH AFFINITY CHIMERIC ANTIGEN RECEPTOR (CAR) HAVING CROSS-REACTIVITY TO CLINICALLY RELEVANT EGFR MUTETED PROTEINS
MX2021013368A (es) * 2019-04-30 2021-11-25 Atara Biotherapeutics Inc Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
WO2020227447A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors targeting glypican-2
WO2020237227A1 (en) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Circular rna compositions and methods
JP2022535138A (ja) * 2019-06-07 2022-08-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃｄ２８および４－１ｂｂに個々に連結したデュアルｃａｒを発現するｔ細胞
WO2021019472A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
EP4021464A4 (en) * 2019-08-27 2024-01-03 Univ Pennsylvania SYNTHETIC CARS FOR TREATING IL13Ra2 POSITIVE HUMAN OR CANINE TUMORS
TW202134278A (zh) * 2019-11-08 2021-09-16 美商胡曼尼根公司 用於治療腫瘤之ｅｐｈａ３導向ｃａｒ－ｔ細胞
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
CN113106067A (zh) * 2020-01-10 2021-07-13 南京大学 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
EP3892720A1 (en) * 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
IL297874A (en) * 2020-05-05 2023-01-01 Regeneron Pharma Car containing cd28 zeta and cd3 zeta
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN116600819A (zh) * 2020-12-09 2023-08-15 艾弗依姆恩治疗公司 靶向epcam和icam-1的双嵌合抗原受体
CN114685683A (zh) * 2020-12-31 2022-07-01 博生吉医药科技(苏州)有限公司 靶向gd2的car-t细胞及其制备和应用
WO2023168436A1 (en) * 2022-03-03 2023-09-07 Board Of Regents, The University Of Texas System Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof
CN114573711A (zh) * 2022-03-04 2022-06-03 陕西师范大学 一种TanCAR的构建及其应用
CN114605560B (zh) * 2022-03-30 2024-02-20 江苏蒙彼利生物科技有限公司 一种car-nk细胞及其制备方法与应用
CN117338914A (zh) * 2023-10-27 2024-01-05 中山市珈钰生物医药有限公司 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
WO1994000143A1 (en) 1992-06-01 1994-01-06 New England Medical Center Hospitals, Inc. Blocking intercellular interactions with cd43 chimeric molecules
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
GB0015119D0 (en) 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
AU2001270252B2 (en) 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
WO2002077029A2 (en) 2000-11-07 2002-10-03 City Of Hope Cd19-specific redirected immune cells
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
US20050004017A1 (en) 2001-09-18 2005-01-06 Yuval Reiss Methods and compositions for treating hcap associated diseases
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
MXPA04009809A (es) 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
WO2004029284A2 (en) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US20040158329A1 (en) 2003-02-10 2004-08-12 Waldemar Link (Gmbh & Co.) Hip joint prosthesis with shaft inserted into femur
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20060160090A1 (en) 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
WO2005017102A2 (en) 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
JP4772674B2 (ja) 2003-07-21 2011-09-14 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途
WO2005040212A2 (en) 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
CN101426521A (zh) 2005-12-21 2009-05-06 医疗免疫有限责任公司 EPHA2 BiTE分子及其应用
JP2009538144A (ja) 2006-05-22 2009-11-05 ハイプロセル・リミテッド・ライアビリティ・カンパニー 真核細胞株を用いたタンパク質産生
WO2008012237A1 (en) 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
CN101828113B (zh) 2007-07-25 2014-04-16 德国弗劳恩霍夫协会债权安格万特学术研究所 自结合重组抗体融合蛋白
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
DK2279253T3 (en) 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CN105624193B (zh) 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010141543A1 (en) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
SI2496698T1 (sl) 2009-11-03 2019-07-31 City Of Hope Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
CN103502439B (zh) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
EP2714936B1 (en) 2011-06-01 2018-12-12 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
CN103649125A (zh) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
ITRM20120058A1 (it) 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
CN104159917A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 使用icos基cars增强抗肿瘤活性和car持久性
CA2869562C (en) 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013177533A1 (en) 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US20140056868A1 (en) 2012-05-30 2014-02-27 University of Washington Center for Commercialization Supercoiled MiniVectors as a Tool for DNA Repair, Alteration and Replacement
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
JP6079775B2 (ja) 2012-06-01 2017-02-15 日本電気株式会社 スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム
RU2700765C2 (ru) * 2012-08-20 2019-09-19 Фред Хатчинсон Кансэр Рисёч Сентер Способ и композиции для клеточной иммунотерапии
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
EP3597215A1 (en) 2012-10-02 2020-01-22 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP2964753B1 (en) 2013-03-07 2018-04-25 Baylor College of Medicine Targeting cd138 in cancer
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9701758B2 (en) 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide
BR112016009898A2 (pt) * 2013-10-31 2017-12-05 Hutchinson Fred Cancer Res células-tronco/progenitoras hematopoiéticas e efetoras não-t modificadas e usos das mesmas
CA2930215C (en) * 2013-11-21 2021-04-27 Ucl Business Plc A cell comprising more than one chimeric antigen receptor
JP2017504601A (ja) 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
CA2936501A1 (en) * 2014-01-13 2015-07-16 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US10865242B2 (en) 2014-04-10 2020-12-15 Seattle Children's Hospital Method and compositions for cellular immunotherapy
KR102110187B1 (ko) 2014-05-14 2020-05-14 카르스젠 테라퓨틱스 리미티드 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구
EP3798233A1 (en) 2014-06-02 2021-03-31 The United States of America, as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting cd-19
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
BR112017008710A8 (pt) 2014-10-27 2023-04-25 Hutchinson Fred Cancer Res Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2016275030B2 (en) 2015-06-10 2021-12-09 Nantkwest, Inc. Modified NK-92 cells for treating cancer
ES2961346T3 (es) 2015-06-12 2024-03-11 Lentigen Tech Inc Procedimiento para tratar cáncer con células T modificadas genéticamente
EP3331920A4 (en) 2015-08-07 2019-04-03 Seattle Children's Hospital, dba Seattle Children's Research Institute T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING
IL287889B2 (en) 2016-02-05 2024-03-01 Hope City Administration of transgenic T cells for the treatment of central nervous system cancer
CN109415409B (zh) 2016-04-01 2022-03-15 亘喜生物科技（上海）有限公司 Flag标记的cd19-car-t细胞
EP3518972A4 (en) 2016-09-28 2020-07-22 Kite Pharma, Inc. ANTIGEN BINDING MOLECULES AND THEIR METHODS OF USE
DK3523326T3 (da) 2016-10-04 2020-08-03 Prec Biosciences Inc Samstimulerende domæner til anvendelse i genetisk modificerede celler
EP3551197B1 (en) 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US11104732B2 (en) 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15

Also Published As

Publication number Publication date
CN108174604A (zh) 2018-06-15
JP2022119759A (ja) 2022-08-17
JP2018522567A (ja) 2018-08-16
AU2016306209B2 (en) 2023-07-06
US11123369B2 (en) 2021-09-21
HK1256087A1 (zh) 2019-09-13
US20200215108A1 (en) 2020-07-09
EP3331920A1 (en) 2018-06-13
JP7162530B2 (ja) 2022-10-28
US20230130938A1 (en) 2023-04-27
EP3331920A4 (en) 2019-04-03
CN108174604B (zh) 2023-06-23
US20210085719A1 (en) 2021-03-25
WO2017027291A1 (en) 2017-02-16
AU2016306209A1 (en) 2018-03-15
AU2023241321A1 (en) 2023-10-26
US11458167B2 (en) 2022-10-04
CA2994829A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
MX2018001568A (es) Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
AU2023200884B2 (en) Human mesothelin chimeric antigen receptors and uses thereof
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
MX2020001450A (es) Composiciones para reducir la inmunosupresion por celulas de tumor.
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
CY1121979T1 (el) Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
MX2020002901A (es) Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
GB2564823A8 (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
EA202091566A1 (ru) Содержащая нуклеиновую кислоту липидная наночастица и ее применение
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
WO2011062997A3 (en) Human monoclonal antibodies to human nucleolin
MX2020004243A (es) Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
BR112016024957A2 (pt) métodos aperfeiçoados para fabricação de terapias celulares adotivas
PH12016501976A1 (en) Antibodies, pharmaceutical compositions and uses thereof
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.